论文部分内容阅读
目的:观察肝康宁片联合拉米夫定对慢性乙型肝炎患者肝功能变化及T细胞亚群的影响。方法:将112例慢性乙型肝炎患者随机分为2组各56例,对照组予拉米夫定治疗,观察组在对照组的基础上加用肝康宁片治疗;均连续治疗6月,观察比较2组患者治疗前、治疗3月、6月ALT、AST、TBil、Alb、HBV-DNA载量及T细胞亚群水平变化。结果:治疗3、6月,2组HBV-DNA载量较治疗前逐渐下降(P<0.05);治疗6月观察组HBV-DNA载量低于对照组(P<0.05)。2组治疗3、6月TBil、ALT、AST水平较治疗前下降(P<0.05);治疗6月Alb水平较治疗前升高(P<0.05)。治疗6月,观察组TBil、ALT、AST水平低于对照组(P<0.05),Alb水平高于对照组(P<0.05)。治疗3、6月,2组CD4+、CD8+、CD4+/CD8+均较治疗改善(P<0.05);且治疗组上述指标改善优于对照组(P<0.05)。治疗6月,2组CD3+水平均较治疗前改善(P<0.05);但2组间比较差异无统计学意义(P>0.05)。结论:肝康宁片联合拉米夫定治疗慢性乙型肝炎疗效优于单纯西药治疗,值得临床推广应用。
Objective: To observe the effect of Hekangning tablets combined with lamivudine on hepatic function and T cell subsets in patients with chronic hepatitis B. Methods: One hundred and twenty-two patients with chronic hepatitis B were randomly divided into two groups of 56 cases each. The control group was treated with lamivudine. The observation group was treated with Hekangning tablets on the basis of the control group. All the patients were treated continuously for 6 months. The changes of ALT, AST, TBil, Alb, HBV-DNA load and T cell subsets in two groups before treatment, three months and six months of treatment were compared. Results: After 3 and 6 months of treatment, the HBV-DNA load of 2 groups decreased gradually (P <0.05). The HBV-DNA load of the observation group in June was lower than that of the control group (P <0.05). The levels of TBil, ALT and AST decreased in both groups at 3 and 6 months after treatment (P <0.05). Alb levels in treatment group were significantly higher than those before treatment (P <0.05). At 6 months, the levels of TBil, ALT and AST in the observation group were lower than those in the control group (P <0.05), and the levels of Alb in the observation group were higher than those in the control group (P <0.05). The levels of CD4 +, CD8 + and CD4 + / CD8 + in the two groups were better than those in the treatment group (P <0.05). The improvement of the above indexes in the treatment group was better than that in the control group (P <0.05). The levels of CD3 + in both groups were improved after treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion: Gancomeng tablets combined with lamivudine in the treatment of chronic hepatitis B is superior to western medicine alone, which is worthy of clinical application.